Platelet PAR-1 Activation in Health and Diabetes
- Conditions
- Type 2 DiabetesHealthy
- Registration Number
- NCT04280549
- Lead Sponsor
- Vanderbilt University Medical Center
- Brief Summary
Platelet activation has been associated with bad events like heart attack and stroke. There are a variety of platelet activators that regulate how active a platelet is. We are interested in Protease-activated receptors (PAR)-1. We are currently studying PAR-1 activation in persons with severe peripheral artery disease. We seek, through this project, to understand PAR-1 activation in persons without peripheral artery disease. As many patients with peripheral artery disease have diabetes, we will also evaluate PAR-1 activation in persons with type 2 diabetes. In addition we will assess the impact of the glucagon-like peptide (GLP)-1 signaling pathway on platelet activation. Levels of platelet activation will be determined using platelet aggregation experiments and assessment of platelet-monocyte aggregates in peripheral blood.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- Healthy men and women ≥60 years of age OR
- Type 2 diabetic men and women ≥60 years of age
- Active cancer
- Prior myocardial infarction, prior stroke, diagnosed peripheral artery disease
- Severe liver (cirrhosis, cancer, or end-stage liver disease), kidney disease (eGFR <30 cc/min).
- Pregnancy or lactation
- Active vasculitis
- Anticipated lifespan < 2 years
- Current use of a DOAC
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Platelet Activation One day Number of dilysyl-MDA cross-links formed in human platelets
Protease Activated Receptor-1 Activation One day Number of cleaved PAR-1 receptors in proportion to number of uncleared PAR-1 receptors
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States